Alka Khichi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Alka Khichi has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Mehak Dangi
Centre for Bioinformatics, Maharshi Dayanand University, Rohtak, Haryana, India
3 shared publications - Anil Kumar Chhillar
Centre for Biotechnology, Maharshi Dayanand University, Rohtak, India
2 shared publications - Ritu Jakhar
Centre for Bioinformatics, Maharshi Dayanand University, Rohtak, 124001, India
2 shared publications - Bhoomika1 shared publication
- Deepak Sharma
Department of Pulmonary and Critical Care Medicine, King George's Medical University, Lucknow
1 shared publication - Dev Kumar
Centre for Bioinformatics, Maharshi Dayanand University, Rohtak, 124001, India
1 shared publication
Latest Publications
- 1 September 2026
- Published by Bentham Science Publishers Ltd. in Current Computer-Aided Drug Design
- Vol. 22, 1-17
Computational Discovery of Phytochemicals Targeting InhA of Mycobacterium tuberculosis: Insights from Molecular Docking, MMGBSA, ADME Profiling, and Molecular Dynamics Simulations
Introduction: Tuberculosis (TB) is one of the most serious global health issues, with the increasing number of multidrug-resistant TB cases emphasizing the need for new therapeutic approaches. Phytochemicals, with their diverse structures and favorable safety profiles, are a largely unexplored area for anti-TB drug development. Methods: An ethnobotanical study and literature analysis identified 310 medicinal plants traditionally used to treat respiratory infections, which produced 4,087 phytochemicals. Their structures were obtained from PubChem or drawn using ChemDraw, and pharmacokinetic properties were analyzed using QikProp. Enoyl-acyl carrier protein reductase (InhA, PDB ID: 4TRO), an important enzyme involved in mycolic acid biosynthesis, was selected as the target protein. Molecular docking was performed using Glide, followed by MMGBSA calculations, and the best hits were validated by 300 ns molecular dynamics simulations using the GROMACS pipeline. Results: Binding affinities showed that four phytochemicals, namely Patuletin, skimmin, flavonol- 3-O-D-glycoside, and salicin, had significantly higher binding affinity scores (-10.06 to -8.82 kcal/mol) than first-line anti-TB drugs isoniazid (-6.35 kcal/mol) and pyrazinamide (-4.22 kcal/mol). Patuletin and skimmin had MM-GBSA binding affinity scores of -74.89 and -71.76 kcal/mol, respectively. MD simulations of the top 3 compounds and control showed that the protein-ligand complexes were stable, as indicated by the RMSD, RMSF, Radius of gyration, SASA, and HBONDS. Discussion: Patuletin and Skimmin demonstrated strong binding affinity and structural stability against the InhA enzyme (PDB: 4TRO), indicating their potential as promising lead compounds for anti-tuberculosis effects. Derived from ethnomedicinal plants, these phytochemicals not only target key mycobacterial pathways but may also offer hepatoprotective and immunomodulatory benefits. The findings support the exploration of plant-derived compounds as safer and effective alternatives or adjuncts to conventional anti-TB therapies. Conclusion: The combination of virtual screening, ADME studies, and MD simulations enabled the identification of phytochemicals with promising interactions toward InhA, an established anti-TB target. The findings are based solely on computational analysis and should be interpreted as preliminary evidence of target engagement rather than confirmed inhibitory activity or therapeutic efficacy. These natural products may serve as potential lead compounds for further anti-tubercular drug discovery, warranting subsequent biochemical, cellular, and in vivo validation to establish their inhibitory potential, safety, and pharmacological effectiveness.
- 1 September 2026
- Published by Bentham Science Publishers Ltd. in Current Computer-Aided Drug Design
- Vol. 22, 1-17
Computational Discovery of Phytochemicals Targeting InhA of Mycobacterium tuberculosis: Insights from Molecular Docking, MMGBSA, ADME Profiling, and Molecular Dynamics Simulations
Introduction: Tuberculosis (TB) is one of the most serious global health issues, with the increasing number of multidrug-resistant TB cases emphasizing the need for new therapeutic approaches. Phytochemicals, with their diverse structures and favorable safety profiles, are a largely unexplored area for anti-TB drug development. Methods: An ethnobotanical study and literature analysis identified 310 medicinal plants traditionally used to treat respiratory infections, which produced 4,087 phytochemicals. Their structures were obtained from PubChem or drawn using ChemDraw, and pharmacokinetic properties were analyzed using QikProp. Enoyl-acyl carrier protein reductase (InhA, PDB ID: 4TRO), an important enzyme involved in mycolic acid biosynthesis, was selected as the target protein. Molecular docking was performed using Glide, followed by MMGBSA calculations, and the best hits were validated by 300 ns molecular dynamics simulations using the GROMACS pipeline. Results: Binding affinities showed that four phytochemicals, namely Patuletin, skimmin, flavonol- 3-O-D-glycoside, and salicin, had significantly higher binding affinity scores (-10.06 to -8.82 kcal/mol) than first-line anti-TB drugs isoniazid (-6.35 kcal/mol) and pyrazinamide (-4.22 kcal/mol). Patuletin and skimmin had MM-GBSA binding affinity scores of -74.89 and -71.76 kcal/mol, respectively. MD simulations of the top 3 compounds and control showed that the protein-ligand complexes were stable, as indicated by the RMSD, RMSF, Radius of gyration, SASA, and HBONDS. Discussion: Patuletin and Skimmin demonstrated strong binding affinity and structural stability against the InhA enzyme (PDB: 4TRO), indicating their potential as promising lead compounds for anti-tuberculosis effects. Derived from ethnomedicinal plants, these phytochemicals not only target key mycobacterial pathways but may also offer hepatoprotective and immunomodulatory benefits. The findings support the exploration of plant-derived compounds as safer and effective alternatives or adjuncts to conventional anti-TB therapies. Conclusion: The combination of virtual screening, ADME studies, and MD simulations enabled the identification of phytochemicals with promising interactions toward InhA, an established anti-TB target. The findings are based solely on computational analysis and should be interpreted as preliminary evidence of target engagement rather than confirmed inhibitory activity or therapeutic efficacy. These natural products may serve as potential lead compounds for further anti-tubercular drug discovery, warranting subsequent biochemical, cellular, and in vivo validation to establish their inhibitory potential, safety, and pharmacological effectiveness.
- 1 July 2021
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Biotechnology
- Vol. 22 (8) , 1030-1045
Growing Preferences towards Analog-based Drug Discovery
Background: The major concern of today's time is the developing resistance in the most of the clinically derived pathogenic micro-organisms for the available drugs through several mechanisms. So, there is an acute need to develop novel molecules with drug like properties that can be effective against the otherwise resistant micro-organisms. Methods: New drugs can be developed using several methods like structure based drug design, ligand based drug design or by developing analogues of the available drugs to improve their effect further. But the smartness is to opt for the techniques that involve lower expenditure, lower failure rates and faster discovery rates. Results: Analogue based drug design (ABDD) is one such technique that researchers worldwide are opting to develop new drug like molecules with comparatively lower market values.They start by first designing the analogues sharing structural and pharmacological similarities to the existing drugs. This method embark on scaffold structures of available drugs already approved by the clinical trials, but are left ineffective because of resistance developed by the pathogens. Conclusion: In this review we have stated some recent examples of anti-fungal and anti-bacterial (antimicrobial) drugs that were designed based on ABDD technique. Also we have tried to focus on the in silico tools and techniques that can contribute for the designing and computational screening of the analogues, so that these can be further taken for in vitro screening to validate their better biological activities against the pathogens with comparatively reduced rates of failure.
- 1 July 2021
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Biotechnology
- Vol. 22 (8) , 1030-1045
Growing Preferences towards Analog-based Drug Discovery
Background: The major concern of today's time is the developing resistance in the most of the clinically derived pathogenic micro-organisms for the available drugs through several mechanisms. So, there is an acute need to develop novel molecules with drug like properties that can be effective against the otherwise resistant micro-organisms. Methods: New drugs can be developed using several methods like structure based drug design, ligand based drug design or by developing analogues of the available drugs to improve their effect further. But the smartness is to opt for the techniques that involve lower expenditure, lower failure rates and faster discovery rates. Results: Analogue based drug design (ABDD) is one such technique that researchers worldwide are opting to develop new drug like molecules with comparatively lower market values.They start by first designing the analogues sharing structural and pharmacological similarities to the existing drugs. This method embark on scaffold structures of available drugs already approved by the clinical trials, but are left ineffective because of resistance developed by the pathogens. Conclusion: In this review we have stated some recent examples of anti-fungal and anti-bacterial (antimicrobial) drugs that were designed based on ABDD technique. Also we have tried to focus on the in silico tools and techniques that can contribute for the designing and computational screening of the analogues, so that these can be further taken for in vitro screening to validate their better biological activities against the pathogens with comparatively reduced rates of failure.
- 10 April 2019
- Published by Bentham Science Publishers Ltd. in Current Bioinformatics
- Vol. 14 (4) , 323-332
An Integrated Chikungunya Virus Database to Facilitate Therapeutic Analysis: ChkVDb
Chikungunya infection flare-ups have happened in nations of Africa, Asia, and Europe including Indian and Pacific seas. It causes fever and different side effects incorporate muscle torment, migraine, sickness, exhaustion and rash. It has turned into another, startling general medical issue in numerous tropical African and Asian countries and is presently viewed as a genuine risk. There is no antiviral treatment and vaccine available for this ailment and the treatment is centered just on mitigating the side effects. Therefore, to encourage the study on this viral pathogen, we have developed a database that annotates and unifies the data from various resources; ChkVDb. It is a consolidated approach for Chikungunya Virus genomic, proteomic, phylogenetics and therapeutic learning. It involves entire genome sequences and their annotation utilizing different in silico tools. Annotation includes the information for CpG Island, usage bias, codon context and phylogenetic analysis at both genome and proteome level. This database incorporates information of 41 strains of virus causing Chikungunya infection that can be accessed conveniently as well as downloaded effortlessly. Therapeutics section of this database contains data about B and T cell Epitopes, siRNAs and miRNAs that can be used as potential therapeutic targets. This database can be explored by specialists and established researchers around the world to assist their research on this non- treatable virus. Availability: It is a public database available from “www.chkv.in”.
- 10 April 2019
- Published by Bentham Science Publishers Ltd. in Current Bioinformatics
- Vol. 14 (4) , 323-332
An Integrated Chikungunya Virus Database to Facilitate Therapeutic Analysis: ChkVDb
Chikungunya infection flare-ups have happened in nations of Africa, Asia, and Europe including Indian and Pacific seas. It causes fever and different side effects incorporate muscle torment, migraine, sickness, exhaustion and rash. It has turned into another, startling general medical issue in numerous tropical African and Asian countries and is presently viewed as a genuine risk. There is no antiviral treatment and vaccine available for this ailment and the treatment is centered just on mitigating the side effects. Therefore, to encourage the study on this viral pathogen, we have developed a database that annotates and unifies the data from various resources; ChkVDb. It is a consolidated approach for Chikungunya Virus genomic, proteomic, phylogenetics and therapeutic learning. It involves entire genome sequences and their annotation utilizing different in silico tools. Annotation includes the information for CpG Island, usage bias, codon context and phylogenetic analysis at both genome and proteome level. This database incorporates information of 41 strains of virus causing Chikungunya infection that can be accessed conveniently as well as downloaded effortlessly. Therapeutics section of this database contains data about B and T cell Epitopes, siRNAs and miRNAs that can be used as potential therapeutic targets. This database can be explored by specialists and established researchers around the world to assist their research on this non- treatable virus. Availability: It is a public database available from “www.chkv.in”.